Aadi Bioscience Q4 GAAP EPS $(0.60) Beats $(0.65) Estimate, Sales $6.33M Beat $6.29M Estimate
Portfolio Pulse from Benzinga Newsdesk
Aadi Bioscience reported Q4 GAAP EPS of $(0.60), surpassing the $(0.65) estimate, and sales of $6.33M, slightly above the $6.29M estimate. This represents a decrease in losses per share but an increase in sales compared to the same period last year.
March 13, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aadi Bioscience surpassed Q4 earnings and sales estimates, indicating potential positive momentum for the stock.
Beating both earnings and sales estimates typically generates positive investor sentiment, potentially leading to a short-term increase in stock price. The improvement in sales year-over-year further supports a positive outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100